rs34557412 — TNFRSF13B TACI C104R

TACI C104R — When the B-Cell's Survival Signal Goes Silent

Every antibody that defends you against a repeated infection — from the IgA that coats your gut to the IgG that neutralises a pathogen in your blood — depends on a molecular conversation between B cells and their survival signals. TACI (Transmembrane Activator and Calcium modulator and cyclophilin ligand Interactor)¹¹ TACI (Transmembrane Activator and Calcium modulator and cyclophilin ligand Interactor)
TACI is encoded by TNFRSF13B and expressed mainly on mature B cells and plasma cells; it binds the cytokines BAFF and APRIL to regulate B-cell differentiation, class-switch recombination, and immunoglobulin secretion is the receptor that receives those survival signals. The C104R variant (rs34557412) swaps a cysteine for an arginine at position 104 in TACI's ligand-binding domain — precisely the cysteine residue that forms a disulfide bridge required for proper receptor folding. The result is a malformed receptor that cannot bind its ligands and, more dangerously, actively sabotages the wild-type copies it assembles with.

This makes C104R the most consequential known non-HLA risk factor for infection susceptibility and the most penetrant genetic cause of common variable immunodeficiency (CVID). It is rare — about 1% of Europeans carry one copy — but the functional consequences in carriers are measurable at the population level and clinically serious in a subset.

The Mechanism

TACI forms oligomeric receptor complexes before ligand binding — the subunits pre-assemble in the membrane even before BAFF or APRIL arrives. This is critical for understanding why C104R is so damaging. Because the mutant receptor integrates into the same oligomeric complex as wild-type TACI, it cannot be simply ignored. Garibyan et al. demonstrated in 2007²² Garibyan et al. demonstrated in 2007
the dominant-negative effect was confirmed by co-immunoprecipitation in cells co-expressing WT and C104R TACI; the corresponding murine mutant C76R showed identical effects that C104R dominantly interferes with signaling by blocking ligand-induced receptor rearrangement — not by preventing ligand binding itself, but by freezing the oligomeric complex in a non-signaling conformation. A single mutant subunit can silence the entire receptor cluster.

The downstream consequences are predictable: without TACI signaling, B cells fail to undergo class-switch recombination³³ class-switch recombination
the process by which B cells change from producing IgM to producing IgG, IgA, or IgE — essential for producing antibodies tailored to the pathogen's surface. Without class switching, the adaptive immune response cannot generate the specific, high-affinity antibodies that prevent re-infection. B cells from C104R carriers express surface TACI normally but produce negligible IgG and IgA in response to APRIL stimulation. At the chromatin level, multi-omics analysis⁴⁴ multi-omics analysis
naïve B cells from C104R carriers showed 8% less accessible chromatin at baseline; class-switched memory B cells showed 25% less reveals a genome-wide silencing of B-cell activation programs — with dysregulated NF-κB and MAPK signalling confirmed by flow cytometry.

The Evidence

Discovery and CVID connection. Two concurrent Nature Genetics papers in 2005⁵⁵ Nature Genetics papers in 2005
Castigli et al. and Salzer et al. were published back-to-back and together established TNFRSF13B as the first non-HLA gene associated with CVID established TNFRSF13B mutations as a cause of CVID and IgA deficiency. Castigli et al. found TACI mutations in 4 of 19 CVID patients and 1 of 16 IgAD patients, absent in all 50 healthy controls. Salzer et al. identified mutations in 13 CVID patients, with homozygous C104R abolishing APRIL binding and class switching entirely. Combined population analysis found TNFRSF13B mutation frequency of 9.9% in CVID patients vs. 3.2% in controls⁶⁶ TNFRSF13B mutation frequency of 9.9% in CVID patients vs. 3.2% in controls
p<10⁻⁶ across Czech, Canadian, and European populations; C104R was the most frequent single mutation detected.

Infection susceptibility at the population level. A [genome-wide association study of

200,000 Europeans | Tian et al. Nature Communications 2017; 23 infection phenotypes tested including tonsillectomy, childhood ear infection, strep throat, pneumonia, and others](https://pubmed.ncbi.nlm.nih.gov/28928442/⁷⁷ https://pubmed.ncbi.nlm.nih.gov/28928442/) found rs34557412 to be the strongest non-HLA association with infection susceptibility, with an odds ratio of 1.59 (p=3×10⁻²¹) for tonsillectomy and nominally significant association with childhood ear infection (p=2×10⁻⁶). Tonsillectomy in this context is a proxy for recurrent tonsillitis — the tonsillar B-cell microenvironment is particularly dependent on TACI-mediated switching to IgA, and its failure manifests as chronic mucosal infections requiring surgical removal.

Blood cell effects. A large GWAS of haematological traits⁸⁸ large GWAS of haematological traits
Astle et al. Cell 2016; 127,000+ individuals from UK Biobank and other cohorts found significant associations between the G allele and reduced monocyte count (p=3×10⁻²⁷), reduced lymphocyte count (p=2×10⁻¹⁰), and reduced platelet count (p=2×10⁻¹¹). These effects reflect TACI's role in shaping the composition of circulating immune cells, consistent with impaired B-cell differentiation and survival.

Autoimmunity paradox. Despite causing immunodeficiency, C104R carriers paradoxically show elevated autoimmune complications. This reflects a fundamental feature of TACI biology: TACI is not only a survival signal but also a negative regulator of autoreactive B cells. Heterozygous carriers show impaired elimination of autoreactive clones — the dominant-negative mechanism disrupts both the pro-survival and the tolerance-maintaining arms of TACI signalling.

Practical Actions

The actionable implications of C104R focus on immunoglobulin monitoring and infection vigilance. Carriers who develop symptomatic hypogammaglobulinemia (low IgG or IgA) may qualify for immunoglobulin replacement therapy, which is highly effective at preventing recurrent bacterial infections in CVID. Even asymptomatic carriers warrant baseline immunoglobulin quantification, as subclinical IgA or IgG deficiency may go unrecognized until a serious infection occurs.

For heterozygous carriers, the dominant-negative mechanism means the practical risk lies between the normal and homozygous extremes. Many heterozygous C104R carriers remain subclinically affected — their infection burden is elevated but they do not meet formal CVID diagnostic criteria. Regular immunoglobulin monitoring and a low threshold for medical evaluation of recurrent infections are the cornerstones of management.

Interactions

CVID is polygenic in most cases. TACI mutations are neither necessary nor sufficient for CVID — they increase susceptibility, and additional genetic or environmental triggers determine whether frank immunodeficiency develops. Combinations with variants in BAFF (rs9514828, rs1048990), the BAFF receptor TNFRSF13C, or MSH5 at the MHC region have been proposed as modifiers. The GWAS data showing tonsillectomy association (OR 1.59) reflects the penetrance of the variant in an unselected general population — most G allele carriers do not have a formal CVID diagnosis but carry measurable immune disadvantage across their lifetime.